681 related articles for article (PubMed ID: 16511671)
1. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
[TBL] [Abstract][Full Text] [Related]
2. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
3. Metastatic neuroendocrine hepatic tumors: resection improves survival.
Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
[TBL] [Abstract][Full Text] [Related]
4. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
Chambers AJ; Pasieka JL; Dixon E; Rorstad O
Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors.
Jensen EH; Kvols L; McLoughlin JM; Lewis JM; Alvarado MD; Yeatman T; Malafa M; Shibata D
Ann Surg Oncol; 2007 Feb; 14(2):780-5. PubMed ID: 17146740
[TBL] [Abstract][Full Text] [Related]
6. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.
Ho AS; Picus J; Darcy MD; Tan B; Gould JE; Pilgram TK; Brown DB
AJR Am J Roentgenol; 2007 May; 188(5):1201-7. PubMed ID: 17449759
[TBL] [Abstract][Full Text] [Related]
8. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors.
Yao KA; Talamonti MS; Nemcek A; Angelos P; Chrisman H; Skarda J; Benson AB; Rao S; Joehl RJ
Surgery; 2001 Oct; 130(4):677-82; discussion 682-5. PubMed ID: 11602899
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatic metastases of neuroendocrine malignancies: a 10-year experience.
Dejong CH; Parks RW; Currie E; Piris J; Redhead DN; Garden OJ
J R Coll Surg Edinb; 2002 Apr; 47(2):495-9. PubMed ID: 12018694
[TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases.
Kamat PP; Gupta S; Ensor JE; Murthy R; Ahrar K; Madoff DC; Wallace MJ; Hicks ME
Cardiovasc Intervent Radiol; 2008; 31(2):299-307. PubMed ID: 17922160
[TBL] [Abstract][Full Text] [Related]
11. Management of hepatic metastasis of gastrointestinal carcinoid tumors.
Landry CS; Scoggins CR; McMasters KM; Martin RC
J Surg Oncol; 2008 Mar; 97(3):253-8. PubMed ID: 18264984
[TBL] [Abstract][Full Text] [Related]
12. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.
Eriksson BK; Larsson EG; Skogseid BM; Löfberg AM; Lörelius LE; Oberg KE
Cancer; 1998 Dec; 83(11):2293-301. PubMed ID: 9840528
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
14. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver.
Ruutiainen AT; Soulen MC; Tuite CM; Clark TW; Mondschein JI; Stavropoulos SW; Trerotola SO
J Vasc Interv Radiol; 2007 Jul; 18(7):847-55. PubMed ID: 17609443
[TBL] [Abstract][Full Text] [Related]
15. Surgery in malignant pancreatic neuroendocrine tumors.
Nguyen SQ; Angel LP; Divino CM; Schluender S; Warner RR
J Surg Oncol; 2007 Oct; 96(5):397-403. PubMed ID: 17469119
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine liver metastases.
Reddy SK; Clary BM
Surg Clin North Am; 2010 Aug; 90(4):853-61. PubMed ID: 20637952
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital.
Rothenstein J; Cleary SP; Pond GR; Dale D; Gallinger S; Moore MJ; Brierley J; Siu LL
Am J Clin Oncol; 2008 Feb; 31(1):64-70. PubMed ID: 18376230
[TBL] [Abstract][Full Text] [Related]
18. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases.
Berber E; Flesher N; Siperstein AE
World J Surg; 2002 Aug; 26(8):985-90. PubMed ID: 12016479
[TBL] [Abstract][Full Text] [Related]
19. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.
Ueno S; Sakoda M; Kubo F; Hiwatashi K; Tateno T; Baba Y; Hasegawa S; Tsubouchi H;
J Hepatobiliary Pancreat Surg; 2009; 16(3):359-66. PubMed ID: 19300896
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive hepatic surgery for neuroendocrine tumors.
McEntee GP; Nagorney DM; Kvols LK; Moertel CG; Grant CS
Surgery; 1990 Dec; 108(6):1091-6. PubMed ID: 1701060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
